| HER2-Positive Gastric Adenocarcinoma studied in …STUDIED_INderived43 of 43show fewer |
|---|
| → studied in | NCT06253650Phase 2 · recruiting Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730373Phase 2 · recruiting First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764875Phase 3 · recruiting A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715931Phase 2 · active not recruiting Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07780968not yet recruiting Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06846996recruiting Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07685704Phase 2 · not yet recruiting Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05514717Phase 1 · terminated A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05955833NA · completed 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532006Phase 3 · recruiting A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332533Phase 2/Phase 3 · not yet recruiting A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07334431Phase 1/Phase 2 · recruiting Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328738Phase 1 · active not recruiting ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04082364Phase 2/Phase 3 · completed Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04727151Phase 1/Phase 2 · terminated TAC T-cells for the Treatment of HER2-positive Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06998771Phase 2 · not yet recruiting JSKN003 Combined Treatment of HER2-positive Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05586061Phase 2 · active not recruiting First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04660929Phase 1 · unknown CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05555251Phase 1/Phase 2 · terminated BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04319757Phase 1 · completed ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06572319Phase 1/Phase 2 · recruiting Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06492317Phase 2 · not yet recruiting RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439550Phase 2 · not yet recruiting Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03330561Phase 1 · completed PRS-343 in HER2-Positive Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03650348Phase 1 · completed PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04602117Phase 1 · withdrawn ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05982834Phase 1/Phase 2 · unknown Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03602079Phase 1/Phase 2 · completed Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04650451Phase 1 · suspended Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05619016Phase 2 · unknown [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05190445Phase 2 · active not recruiting Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05091528Phase 1/Phase 2 · terminated A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03409848Phase 2 · completed Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05313906Phase 2 · unknown RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05311189Phase 2 · unknown Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05270889Phase 2 · unknown Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05165602unknown Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03319459Phase 1 · completed FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05070598Phase 2 · unknown Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04920747completed Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464967Phase 1/Phase 2 · withdrawn Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04520295unknown ctDNA Screening in Advanced HER2 Positive Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02378389Phase 1 · unknown Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer · condition mapped ALIAS · 43 trials mapped (17 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |